About this Research Topic
Biologics represent a breakthrough in the management of airway diseases, offering precision treatments that target specific immune pathways. This special issue, Biologics for Airway Diseases: From Bench to Bedside, will explore the journey of biologics from preclinical research to their clinical use in conditions such as asthma, COPD, and other respiratory disorders. With rapid advancements in both research and clinical practice, biologics have opened new doors for patients who previously had limited options. This collection aims to present the latest findings, share innovative approaches, and foster dialogue on the future of biologics in airway disease treatment.
The main goal of this research topic is to bring together leading research on biologics for airway diseases, providing a comprehensive look at the scientific and clinical progress in this field. We aim to highlight the translational aspects of biologic therapies, focusing on how discoveries in the lab are rapidly being integrated into patient care. This collection seeks to foster collaboration between researchers, clinicians, and industry experts, offering insights that can guide future research directions, clinical applications, and policy-making. By examining both successes and challenges, we hope to advance the understanding and impact of biologics in treating airway diseases.
This research topic invites original research, reviews, and case studies focused on biologics in the context of airway diseases. We encourage submissions that cover various stages of development, from basic research on immune mechanisms to clinical trials and real-world applications. Topics may include biologic therapies for asthma, COPD, and rare respiratory conditions, as well as challenges like patient selection, efficacy, and long-term safety. Authors should present rigorous data and innovative perspectives that push the boundaries of current knowledge. All submissions will undergo peer review, and accepted papers will contribute to advancing biologics in respiratory healthcare.
The main goal of this research topic is to bring together leading research on biologics for airway diseases, providing a comprehensive look at the scientific and clinical progress in this field. We aim to highlight the translational aspects of biologic therapies, focusing on how discoveries in the lab are rapidly being integrated into patient care. This collection seeks to foster collaboration between researchers, clinicians, and industry experts, offering insights that can guide future research directions, clinical applications, and policy-making. By examining both successes and challenges, we hope to advance the understanding and impact of biologics in treating airway diseases.
This research topic invites original research, reviews, and case studies focused on biologics in the context of airway diseases. We encourage submissions that cover various stages of development, from basic research on immune mechanisms to clinical trials and real-world applications. Topics may include biologic therapies for asthma, COPD, and rare respiratory conditions, as well as challenges like patient selection, efficacy, and long-term safety. Authors should present rigorous data and innovative perspectives that push the boundaries of current knowledge. All submissions will undergo peer review, and accepted papers will contribute to advancing biologics in respiratory healthcare.
Keywords: Asthma, COPD, Bronchiectasis, Biologic treatments, Mepolizumab, Reslizumab, Benralizumab, Dupilumab, Tezepelumab, Th2-inflammation, Eosinophilic inflammation, Treatable traits, Precision medicine interventions
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
